Collagen Solution, the developer of collagen solutions in regenerative medicine, has completed a major study into repair cartilage defects in the knee.

Having reached the “last patient out” milestone, its ChondroMimetic implant is one step closer to providing the company with access to a potential $500 million to $1 billion market opportunity.

A clinical study report will be submitted to regulatory authorities when ready, but Collagen said that analysis had indicated that the ChondroMimetic scaffold was virtually indistinguishable from surrounding cartilage at six months following surgery.

Collagen is targeting commercialisation outside the US in mid-2018.